Compare Stocks

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

PowerShares FTSE RAFI Asia Pacific ex-Japan Portfolio (the Fund) is based on the FTSE RAFI Developed Asia Pacific ex Japan Index (Index). The Fund will normally invest at least 90% of its total assets in securities that comprise the Index and American Depositary Receipts (ADRs) based on the securities in the Index. The Index is designed to track the performance of the largest equities of companies domiciled in the Asia Pacific region (excluding Japan), selected based on the four fundamental measures of firm size: book value, income, sales and dividends. The 1000 equities with the highest fundamental strength are weighted according to their fundamental scores. The fundamentally weighted portfolio is rebalanced and reconstituted annually. The Fund invests in consumer discretionary, consumer staples, energy, financials, health care, industrials, information technology and telecommunicaiton services sectors. The Fund's investment advisor is Invesco PowerShares Capital Management LLC.

TMAC Resources Inc. engages in exploring, evaluating, developing, and mining mineral properties in Canada. The company primarily explores for gold deposits. Its principal asset is 100% owned Hope Bay Project covering an area of 1,101 square kilometers located in the Kitikmeot region of western Nunavut Territory. TMAC Resources Inc. was incorporated in 2012 and is headquartered in Toronto, Canada. As of February 2, 2021, TMAC Resources Inc. operates as a subsidiary of Agnico Eagle Mines Limited.